

Medicine Manufacturing The Case for Change in Europe



3,000

patients were surveyed regarding pharmaceutical manufacturing resilience

27 April 2021
-13 May 2021



The supply of medicines has proven to be resilient

Despite the impact of border closures, demand spikes, national hoarding and disruption of healthcare services, COVID-19 has had limited negative impact on the availability of medicines in Europe



73% of patients experienced access to healthcare challenges

90% of patients did not experience more shortages

The pandemic confirms the importance that patients attach to the availability of medication



The pandemic triggered an interest among patients regarding manufacturing

Knowledge about medication manufacturing is limited

Almost **2 in 3**

66% have no idea where medicines are produced, but 70% want to know more



Patients consider Europe as the centre of the pharmaceutical industry



Over-dependencies on other regions for manufacturing medicines concern patients



76%

of patients perceive Europe as being too dependent on other regions



Patients call for support in supply security and manufacturing

84%

of patients want their government to support manufacturing investments to ensure Europe can produce critical medicines

65+

Older patients are especially in favour of this (89%)

72%

More than 7 in 10 patients believe that supply security should be the most important criterion to be considered by health insurers when selecting pharmaceutical companies

74%

Almost 3 in 4 patients also find it important to know that their government cares about attracting medicines manufacturing investments

71%

More than 7 in 10 patients are interested in knowing Europe remains as competitive as other regions



The pharmaceutical industry is considered important in the recovery post Covid

85%

of patients believe the pharmaceutical industry is of key importance to recover from the COVID-19 pandemic

73%

of patients believe it can ensure stability of supply of medicines


59%

of patients believe that it can secure Europe's production sovereignty & autonomy especially for some critical medicines

The most important roles patients expect the industry to fulfill are to...



Bring effective treatments



Drive economic growth



Invest in innovation



Operate responsibly

It is also an important expectation to...



Patients attach benefits to European manufacturing to balance the global supply chain

65% of patients think more positively about a medicine if it is produced in Europe due to perceived economic, social and environmental benefits



Regarding Economic & Social Benefits



Around **6 in 10** patients value the promotion of local jobs and economies alike that come with medication manufacturing in Europe



Around **5 in 10** patients believe that manufacturing of medicines in Europe also means more respect for labour regulations

Regarding Environmental Benefits



Patients believe production in Europe reduces transportation and its impact on the environment



Patients believe production in Europe guarantees greener production with more respect for environmental regulations

65% of patients attach value to knowing their medication production is environmentally sustainable

Almost **2 in 3**



Support, Secure & Inform

Teva's 3 Key Recommendations for Policy Makers



Support the robustness of medicines supply chain




Secure European investment in manufacturing of API and essential medicines



Inform better on Europe's manufacturing capability and capacity

A number-one priority for patients across Europe is an improved reliability of medicines supply to increase confidence

EU must adjust its policies to new economic and technological realities, while expanding its competitiveness and geopolitical position by remaining open and attracting investments



Methodology

Participants: chronic patients*, aged 25+

Data source: online access panels

Data collection: digital survey 10-15 minutes

Time of fieldwork: 27 April to 13 May 2021

Sample: 3,000 in total, 500 in 6 countries, i.e., Croatia (HR), Czech Republic (CZ), France (FR), Germany (DE), Netherlands (NL), Spain (ES)

* 54% of the sample suffers from 1 chronic condition, 45% suffers from multiple chronic conditions. Chronic conditions in survey: Alzheimer's Disease, Arthritis, Asthma, Cancer, Cardiovascular Disease, COPD, Depression, Diabetes, Heart Disease, Hypertension, Hypercholesterolemia, Migraine, Osteoarthritis, Other.

Statistical significance:

Given the robust sample sizes of the study, significant differences between relevant sub-groups in the data (e.g. between markets or between age groups) could be reported with a 95% confidence interval for differences from 4% or more and with a 99% interval for differences of 6% or more. A significant differences means that the difference we see between two relevant analysis groups cannot be explained by chance alone.

The study was conducted by the independent global research agency InSites Consulting.



TEVA'S MISSION is to be a global leader in generics and biopharmaceuticals, improving the lives of more than 200 million patients...

According to Teva's latest Economic Impact Report performed by Matrix Global Advisors (MGA)* in 2021 across 9 EU countries

The company supported **100,000 jobs**

Generated **€4.9B** in labour income

Generated **€25.8B** in economic output

And saved healthcare systems an estimated of **€8.4B** across these markets

*Matrix Global Advisors (MGA) on behalf of Teva: Economic Impact Report 2021. <https://www.tevapharm.com/our-impact/economic-impact-report/>

65% of Teva's global portfolio is manufactured in Europe

96% of Teva medicines sold in Europe are manufactured at Teva's European sites

40% of the APIs that Teva uses in Europe are produced in Europe

TEVA-00074